型号:
产品价格:电议      采购度:1293      原产地:美洲
发布时间:2022/3/28 17:53:00 所属地区:国外 国外
简要描述:
MTI-31 是一种有效的,具有口服活性的,且高度选择性的 mTORC1 和 mTORC2 抑制剂。MTI-31 高选择性作用于 mTOR,Kd 为 nM。MTI-31 对 mTOR 的 IC50 为 39 nM。MTI-31可用于乳腺癌的研究。
标签:mti
产品详情
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 1567915-38-1
MCE 站:MTI-31
产品活性:MTI-31 是一种有效的,具有口服活性的,且高度选择性的 mTORC1 和 mTORC2 抑制剂。MTI-31 高选择性作用于 mTOR,Kd 为 0.20 nM。MTI-31 对 mTOR 的 IC50 为 39 nM。MTI-31可用于乳腺癌的研究。
研究领域:PI3K/Akt/mTOR
作用靶点:mTOR
In Vitro: MTI-31 acts as a potent and selective inhibitor of mTOR enzymatic activity capable of targeting both mTORC1 and mTORC2 functions in cancer cells.
MTI-31 (0.01-100 μM) elicits a potent and more substantial inhibition of cell growth than that of Rapamycin.
Treatment with MTI-31 for 6 h demonstrates a dose-dependent inhibition of both the mTORC1 substrates P-S6K1(T389), P-S6(S235/6), P-4EBP1(T70) and mTORC2 substrate P-AKT(S473), achieving 50% inhibition at ≤0.12 μM in three representative tumor cell lines harboring mTOR pathway dysregulation (786-O renal, U87MG glioma and MDA-MB-453 breast).
MTI-31-induced apoptosis requires mTORC2-regulated Bim- and GSK3 activity.
In Vivo: MTI-31 is a potent mTOR inhibitor in vivo and elicits strong antitumor efficacy. MTI-31(5-40 mg/kg; orally) is efficacious in several tumor models harboring HER2+/PIK3CAmut and/or PTEN-deficiency exemplified by MDA-MB-453 and 786-O.
Treatment of tumor bearing nude mice with orally administered MTI-31 inhibits growth of H1975 tumors (25 mg/kg/d; orally) or U87MG tumors (30 mg/kg/d; orally).
相关产品:Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | PI3K/Akt/mTOR Compound Library | Stem Cell Signaling Compound Library | Anti-Cancer Compound Library | Autophagy Compound Library | Anti-Aging Compound Library | Antioxidants Compound Library | Differentiation Inducing Compound Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Glycolysis Compound Library | Cytoskeleton Compound Library | Orally Active Compound Library | Glutamine Metabolism Compound Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Angiogenesis Related Compound Library | Glucose Metabolism Compound Library | Rapamycin | Everolimus | MHY1485 | Torin 1 | AZD-8055 | Sapanisertib | Dactolisib | 3BDO | JR-AB2-011 | Temsirolimus | Salidroside | Torin 2 | Vistusertib | PI-103 | Torkinib | Omipalisib | L-Leucine | D-α-Hydroxyglutaric acid disodium | PF-04691502 | Dihydromyricetin | KU-0063794 | Samotolisib | Rheb inhibitor NR1 | OSI-027 | Ridaforolimus | Apitolisib | PKI-402 | BGT226 maleate
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 染料试剂 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物;
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果;
• 专业团队跟踪*新的制药及生命科学研究进展,为您提供全球*新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。
更新时间:2024/1/2 10:22:24
留言咨询
温馨提示
1.遵守中华人民共和国有关法律、法规,尊重网上道德,承担一切因您的行为而直接或间接引起的法律责任。
2.请您真实的反映产品的情况,不要捏造、诬蔑、造谣。如对产品有任何疑问,也可以留言咨询。
3.未经本站同意,任何人不得利用本留言簿发布个人或团体的具有广告性质的信息或类似言论。
相关新闻
相关产品